Chronobiological approach to the treatment of patients with benign prostate hyperplasia and chronic prostatitis: results of a morphological examination

Abstract

MATERIALS AND METHODS: 60 patients with benign prostatic hyperplasia (BPH) and category II chronic prostatitis (NIH, 1995) were examined. The average age of the patients was 60.5 ± 5.5 years. The patients were divided into two groups of 30 people each. The comparison group (GC) included patients who received standard therapy with drugs from the group of alpha-blockers and fluoroquinolones. The main group (MG) consisted of patients who received standard therapy in combination with physiotherapy sessions with the device “SMART-PROST”, which were carried out in the acrophase of the chronorhythm. After the end of the course of therapy all patients underwent transurethral resection of the prostate, after which a morphological and morphometric (immunohistochemical) study of the obtained material was carried out.

RESULTS: According to the results of the morphological and morphometric examination of the histological material in patients of the CG and MG, statistically significant differences were revealed in all the studied parameters, which testify to the persistence of signs of the inflammatory process in the CG, while in the MG, the severity of inflammation was significantly lower.

CONCLUSION: According to the results of the study, personalized complex therapy of patients with benign prostatic hyperplasia in combination with chronic prostatitis using a combined physiotherapeutic effect of the SMART-PROST device, taking into account the individual chronobiological characteristics of patients, allows to more effectively arrest the inflammatory process in the prostate tissue, which can lead to a decrease in the number of postoperative complications. However, the last statement requires further more detailed study.

Keywords

chronic bacterial prostatitis / benign prostatic hyperplasia / BPH / TUR of the prostatae / chronotherapy / physiotherapy with the SMART-PROST device / morphometry / immunohistochemistry

References

[1] Alyaev YuG, Glybochko PV, Pushkar’ DYu [editors]. Urologiya. Rossiiskie klinicheskie rekomendatsii. Moscow: GEOTAR-Media, 2018. 480 p. (In Russ.)

[2] Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа; 2018. 480 с.

[3] Gravas S, Cornu JN, Gacci M, et al. Management of non-neurogenic male lower urinary tract symptoms (LUTS) [Internet]. EAUGuideline. 2020 [cited 01.06.2021]. Available from: https: // uroweb.org/guideline/treatment-of-non-neurogenic-male-luts.

[4] Gravas S., Cornu J.N., Gacci M., et al. Management of non-neurogenic male lower urinary tract symptoms (LUTS) [Internet]. EAUGuideline. 2020. Дата обращения: 01.06.2021. Доступ по ссылке: https: // uroweb.org/guideline/treatment-of-non-neurogenic-male-luts.

[5] Roehrborn CG. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. Campbell-Walsh. Urology, 10th edition. 2012. P. 2570–2610. DOI: 10.1016/B978-1-4160-6911-9.00091-8

[6] Roehrborn C.G. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. Campbell-Walsh. Urology, 10th edition. 2012. P. 2570–2610. DOI: 10.1016/B978-1-4160-6911-9.00091-8

[7] Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. Combination drug therapy in patients with BPH. Urologiia. 2018;(1):101–105. (In Russ.) DOI: 10.18565/urology.2018.1.101-105

[8] Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Комбинированная медикаментозная терапия пациентов с аденомой предстательной железы // Урология. 2018. № 1. C. 101–105. DOI: 10.18565/urology.2018.1.101-105

[9] Schaeffer AJ. Classification (Traditional and National Institutes of Health) and Demographics of Prostatitis. Urology. 2002;60(6):5–6. DOI: 10.1016/s0090-4295(02)02292-6

[10] Schaeffer A.J. Classification (Traditional and National Institutes of Health) and Demographics of Prostatitis // Urology. 2002. Vol. 60. No. 6. P. 5–6. DOI: 10.1016/s0090-4295(02)02292-6

[11] Nickel J. Prostatitis. CUA Guidelines. Can Urol Assoc J. 2011;5(5):306–315. DOI: 10.5489/cuaj.11211

[12] Nickel J. Prostatitis. CUA Guidelines // Can Urol Assoc J. 2011. Vol. 5. No. 5. P. 306–315. DOI: 10.5489/cuaj.11211

[13] Rees J, Abrahams M, Doble A, Cooper A. Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116(4):509–525. DOI: 10.1111/bju.13101

[14] Rees J., Abrahams M., Doble A., Cooper A. Prostatitis Expert Reference Group (PERG). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis / chronic pelvic pain syndrome: a consensus guideline // BJU Int. 2015. Vol. 116. No. 4. P. 509–525. DOI: 10.1111/bju.13101

[15] Kudryavcev YuV, Sivkov AV. Morphological alteration in benign prostatic hyperplasia tissue. Experimental & clinical urology. 2010;(1):18–22. (In Russ.)

[16] Кудрявцев Ю.В., Сивков А.В. Морфологические изменения ткани предстательной железы при доброкачественной гиперплазии // Экспериментальная и клиническая урология. 2010. № 1. C. 18–22.

[17] Bartoletti R, Cai T, Mondaini N, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol. 2007;178(6):2411–2415. DOI: 10.1016/j.juro.2007.08.046

[18] Bartoletti R., Cai T., Mondaini N., et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study // J Urol. 2007. Vol. 178. No. 6. P. 2411–2415. DOI: 10.1016/j.juro.2007.08.046

[19] Huang XH, Qin B, Liang YW. LUTS in BPH patients with histological prostatitis before and after transurethral resection of the prostate. Zhonghua Nan KeXue. 2013;19(1):35–39. (In Chinese).

[20] Huang X.H., Qin B., Liang Y.W. LUTS in BPH patients with histological prostatitis before and after transurethral resection of the prostate // Zhonghua Nan KeXue. 2013. Vol. 19. No. 1. P. 35–39.

[21] Krsmanovic A, Tripp D, Nickel J, et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Can Urol Assoc J. 2014;8(11–12):403–408. DOI: 10.5489/cuaj.2179

[22] Krsmanovic A., Tripp D., Nickel J., et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) // Can Urol Assoc J. 2014. Vol. 8. No. 11–12. P. 403–408. DOI: 10.5489/cuaj.2179

[23] Asgari SA, Mohammadi M. The role of intraprostatic inflammation in the acute urinary retention. Int J Prev Med. 2011;2(1):28–31.

[24] Asgari S.A., Mohammadi M. The role of intraprostatic inflammation in the acute urinary retention // Int J Prev Med. 2011. Vol. 2. No. 1. P. 28–31.

[25] Logvinov LA. Kliniko-morfologicheskie kharakteristiki khronicheskogo prostatita [dissertation]. Moscow, 2008. (In Russ.)

[26] Логвинов Л.А. Клинико-морфологические характеристики хронического простатита: дис. … кандидат медицинских наук. Москва, 2008.

[27] Vaupel P, Kelleher DK. Blood flow and oxygenation status of prostate cancers. Adv Exp Med Biol. 2013;765:299–305. DOI: 10.1007/978-1-4614-4989-8_42

[28] Vaupel P., Kelleher D.K. Blood flow and oxygenation status of prostate cancers // Adv Exp Med Biol. 2013. Vol. 765. P. 299–305. DOI: 10.1007/978-1-4614-4989-8_42

[29] Mustafaev AT, Kyzlasov PS, Dianov MP, et al. Surgical treatment of benign prostatic hyperplasia: the past and the present. Urologicheskie vedomosti. 2019;9(1):47–56. (In Russ.) DOI: 10.17816/uroved9147-56

[30] Мустафаев А.Т., Кызласов П.С., Дианов М.П., и др. Хирургическое лечение доброкачественной гиперплазии предстательной железы: прошлое и настоящее // Урологические ведомости. 2019. Т. 9, № 1. C. 47–56. DOI: 10.17816/uroved9147-56

[31] Al’-Shukri SKh, Tkachuk VN, Gorbachev AG, et al. Urodinamicheskie issledovaniya v diagnostike infravezikal’noi obstruktsii u muzhchin. Urologiya i nefrologiya. 1998;(6):27–29. (In Russ.)

[32] Аль-Шукри С.Х., Ткачук В.Н., Горбачев А.Г., и др. Уродинамические исследования в диагностике инфравезикальной обструкции у мужчин // Урология и нефрология. 1998. № 6. С. 27–29.

[33] Kuz’menko AV, Kuz’menko VV, Gyaurgiev TA. The efficacy of fesoterodine in patients after transurethral resection of the prostate. Urologiia. 2019;(1):52–55. (In Russ.) DOI: 10.18565/urology.2019.1.52-55

[34] Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Эффективность применения фезотеродина у больных после трансуретральной резекции предстательной железы // Урология. 2019. № 1. С. 52–55. DOI: 10.18565/urology.2019.1.52-55

[35] Martov AG, Merinov DS, Kornienko SI, et al. Posleoperatsionnye urologicheskie oslozhneniya transuretral’nykh ehlektrokhirurgicheskikh vmeshatel’stv na predstatel’noi zheleze po povodu adenomy. Urologiia. 2006;(2):25–31. (In Russ.)

[36] Мартов А.Г., Меринов Д.С., Корниенко С.И., и др. Послеоперационные урологические осложнения трансуретральных электрохирургических вмешательств на предстательной железе по поводу аденомы // Урология. 2006. № 2. С. 25–31.

[37] Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA, Barannikov II. Chronobiological status of patients with chronic prostatitis and prostate adenoma. System analysis and management in biomedical systems. 2017;16(3):513–516. (In Russ.)

[38] Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А., Баранников И.И. Хронобиологический статус больных хроническим простатитом на фоне аденомы предстательной железы // Системный анализ и управление в биомедицинских системах. 2017. Т. 16. № 3. С. 513–516.

[39] Lanina VA, Khimicheva MN, Kuz’menko VV, et al. Khronobiologicheskie osobennosti bol’nykh s khronicheskim prostatitom pri adenome prostaty. Tendentsii razvitiya nauki i obrazovaniya. 2020;(66–1):111–114. (In Russ.)

[40] Ланина В.А., Химичева М.Н., Кузьменко В.В., и др. Хронобиологические особенности больных с хроническим простатитом при аденоме простаты // Тенденции развития науки и образования. 2020. № 66–1. С. 111–114.

[41] Barannikov II, Kuzmenko AV, Gyaurgiev TA, Kuzmenko VV. Evaluation of the effectiveness of personalized complex therapy in patients with benign prostatic hyperplasia and chronic prostatitis. Urology reports (St. Petersburg). 2021;11(1):39–48. (In Russ.) DOI: 10.17816/uroved56773

[42] Баранников И.И., Кузьменко А.В., Гяургиев Т.А., Кузьменко В.В. Оценка эффективности персонализированной комплексной терапии пациентов с доброкачественной гиперплазией простаты и хроническим простатитом // Урологические ведомости. 2021. Т. 11, № 1. C. 39–48. DOI: 10.17816/uroved56773

[43] Al-Shukri SKh, Gorbachev AG, Borovets SYu, et al. Prostatilen treatment of prostatic adenoma. Urologiia. 2006;(6):22–25. (In Russ.)

[44] Аль-Шукри С.X., Горбачев А.Г., Боровец С.Ю., и др. Лечение больных аденомой предстательной железы простатиленом // Урология. 2006. № 6. С. 22–25.

[45] Bokov AI, Zabelin MV, Kyzlasov PS. Efficiency of physiotherapy treatment of chronic bacterial prostatitis. Urologicheskie vedomosti. 2016;6(1):10–15. (In Russ.) DOI: 10.17816/uroved6110-15.

[46] Боков А.И., Забелин М.В., Кызласов П.С. Эффективность физиотерапевтического лечения хронического бактериального простатита // Урологические ведомости. 2016. Т. 6, № 1. C. 10–15. DOI: 10.17816/uroved6110-15.

RIGHTS & PERMISSIONS

Eco-Vector